2020年度6月定例理事会・委員会会議が開催されました
直近ですと通常京都で開催されていました6月定例理事会・委員会会議がオンラインで開催されました。コロナ禍が始まった昨年度は、予定していた学術集会が急遽取りやめとなり、理事・委員会の先生方も対応に追われていたことと思います。今年は無事オンラインで開催されました。
議題は予め回覧されていました委員会の活動報告・各種情報共有・審議事項の審議でした。必要な情報は追って会員に展開されることでしょう。
2020年度6月定例理事会・委員会会議
JPCERT/CCからJVNとしてWordPressに脆弱性があると報告がありました
本ホームページは、東京大学医学部附属病院に物理的なサーバーがありまして、大学病院医療情報ネットワーク（UMIN）が提供するサービスを利用しています。そのUMINの担当者よりホームページ管理者まで、タイトルの様なセキュリティ上のお知らせが時折入ります。（下表）
本ホームページでは、タイトルにありますWordPressというホームページのコンテンツを管理するシステムを使用しております。ですので、タイトルの様なお知らせが入りましたら、できるだけ速やかにデータベースをバックアップして、最新のバージョンにアップデートします。私自身、そんなに慣れていないこともあって、この作業には１回で数時間を要します。今回は金曜日にお知らせを受信いたしまして、日曜日の午後にその作業を行いました。
（PRC委員長 大島康雄）
表）直近のお知らせの日付とタイトル
日付 タイトル
2019/06/19 WordPressの脆弱性に関する注意喚起
2019/05/30 WordPressの脆弱性に関する注意喚起
2019/03/20 WordPressプラグインに複数の脆弱性
2019/03/06 WordPressプラグインに複数の脆弱性
2019/01/17 WordPressプラグインに複数の脆弱性
2019/01/09 WordPressプラグインに複数の脆弱性
2018/12/20 WordPressに複数の脆弱性
2018/11/14 WordPressプラグインに複数の脆弱性
2018/11/07 WordPressプラグインに複数の脆弱性
2018/07/25 WordPressプラグインに複数の脆弱性
2018/07/11 WordPressプラグインに複数の脆弱性
2018/06/06 WordPressプラグインに複数の脆弱性
2018/05/16 WordPressプラグインに複数の脆弱性
2018/03/14 WordPressプラグインに複数の脆弱性
2018/02/07 WordPressプラグインの脆弱性に関する注意喚起
2017/11/22 WordPressプラグインの脆弱性に関する注意喚起
2017/08/30 WordPressプラグインの脆弱性に関する注意喚起
2017/08/03 WordPressプラグインの脆弱性に関する注意喚起
2017/07/12 WordPressプラグインの脆弱性に関する注意喚起
2017/06/21 WordPressおよびプラグインに複数の脆弱性
2017/06/14 WordPressおよびプラグインに複数の脆弱性
2017/06/06 WordPressおよびプラグインに複数の脆弱性
2017/05/24 WordPressおよび、プラグインの脆弱性に関する注意喚起
2017/04/26 WordPress用プラグインBooking Calendarの脆弱性に関する注意喚起
2017/03/15 WordPressおよびOneThird CMSに脆弱性
2017/02/09 WordPressの脆弱性に関する注意喚起
New Member of Public Relations Committee
Committee: Public Relations Committee
Job Title: Associate Professor
Name: Hiroo Wada
Degree: MD, MBA, PhD, FACP
Institution: Juntendo University
Division/Department: Public Health
Hobby: Tennis, Travel
Message: I believe ACP activities will provide us, physicians, with the applicable knowledge & skills in the fields of clinical medicine and public health.
New Member of Student Committee
Committee: Student Committee
Job Title: Student
Name: Keiko Tsukamoto
Institution: School of Medicine
Division/Department: Tokai University
Hobby: Swimming, Cello, Traveling
Message: Carpe diem
Governor’s Message
Dear ACP members and friends,
I hope you and your families are safe and well.
As covid-19 spreads around the world including this country, I believe all of you, more or less, have involved in the fight against the virus. Thank you for everything for you’re doing on a daily basis to support one another and your patients.
Normally, in this timing of newsletter, I would tell about the success of the recent ACP meeting, the Internal Medicine Meeting 2020, but as you may have already known, it was unfortunately cancelled.
We too had to cancel all the schedule concerning our chapter meeting in June due to this crisis, although now it seems that the first wave of the awful pandemic is passing…
As for the information concerning the pandemic, ACP is compiling first-hand accounts and relevant resources from the internal medicine community during these challenging times, helping you stay informed with the latest articles. You can find the resources on the ACP website. “COVID-19: An ACP Physician’s Guide” is available at the top page. (If it’s not available, access the Clinical Information bar at the top.) It is a great resource provided by ACP!
I look forward to reuniting as a chapter. Until then, stay safe and well.
Sincerely,
Kenji Maeda, MD, FACP
ACP Japan ChapterホームページのPWA化
Progressive Web App (PWA)化とは
このホームページへアクセスする際に、ブラウザを起動して、ホームページのアドレスを入力するか、ブックマークを探してクリックするという方法で見ておられるかたもいらっしゃると思います。それをホーム画面のアイコンをクリックすることでアクセスできるようにすることです。
iOSでPWA化する際の手順です
１．当サイトへiPhone, iPod, iPadのいずれかからアクセスし、画面下の真ん中にあるアイコンをタップします。
私のiPadで試したところ、同様のメニューが右上に現れました。プラットフォームやOSの版によってメニューが表示される場所が異なるかもしれません。
２．下から出てくるメニューで、「ホーム画面に追加」をタップしましょう。
３．「ホーム画面に追加」画面になります。「アイコン」や「アイコンショート名」が正しく表示されているかを確認します。
４．「追加」できるとこんな感じでホーム画面にアイコンが並びます。
５．アプリアイコンをタップすると、こんな感じに全画面で表示されるはずです。（URLバーがない）
（PRC委員長 大島康雄 投稿）
医師のバーンアウトについてのアンケート（Mini-Z2.0日本語版）のご依頼
ACP日本支部Physicians’ Well-being Teamから医師のバーンアウトについてのアンケート（
先生方の身の回りでも医師のバーンアウトは既に身近な問題かと思
アンケートはこちらです↓
対象はACP日本支部会員医師（
なお、アンケートの集計結果については、
ACP日本支部Physicians’ Well-being Team
Governor’s Message
Dear Fellow ACP Japan Chapter Members,
I hope each of you is enjoying a busy but wonderful season.
As the first year of my term as Governor of Japan Chapter, I’d like to express my appreciation for your support. And thanks to the members who helped us spending time and energy, especially lots of thanks to various committee members.
Now we are going internationally. The first Asian Regional Chapters Conference will take place in Kochi in India in August 2020. It was accomplished through endeavors of Governors from India, Bangladesh and South-East Asian Chapters.
The guest speakers from India and Bangladesh will participate in our Chapter meeting in Kyoto in June 2020. There will also be a guest from ACP headquarter in the USA, and we’ll have the first “Thieves’ Market” session in Japan, one of popular sessions in the Internal Medicine Meetings in the USA, which will be presented by Dr. David Scrase.
At the national level, we began to cooperate with both of Japan Primary Care Association and Society for Clinical Epidemiology. Its activity is called as “Primary Care Research Connect” or “PCR Connect”. The first conference of PCR Connect will take place soon in early this month, December 8th. Also we keep cooperating with the Japanese Society of Internal Medicine (JSIM), we are planning to hold a 2nd session with them in the coming JSIM annual meeting in Tokyo in April 2020.
Various committees in our Chapter are acting vigorously. For example, Resident Fellow Committee (RFC) is giving two clinical seminars a year for residents, and International Exchange Program Committee (IEPC) is trying to send young physicians out to oversea medical institutions for short-term study by observation. Other committees are working hard as well. The Japan Chapter is steadily progressing.
The best of the holiday season to you all and your families.
Kenji Maeda, Governor of Japan Chapter
複合語候補ITC103
| 複合語 | スコア |
|---|---|
| heart failure | 11362.654529566 |
| chronic heart failure | 519.90606666886 |
| symptoms of heart failure | 513.21411655139 |
| n engl j med | 390.00549803189 |
| heart failure hospitalization | 356.42102496814 |
| congestive heart failure | 280.57032391471 |
| coronary artery disease | 277.15825556087 |
| j am coll cardiol | 271.7851694969 |
| iv heart failure | 224.04269055375 |
| systolic heart failure | 187.10772077547 |
| heart rate | 177.54273087838 |
| severe heart failure | 171.42592868794 |
| decompensated heart failure | 164.42484855543 |
| ejection fraction | 164.27110467461 |
| incident heart failure | 163.40050263775 |
| et al | 153.3196976963 |
| management of heart failure | 147.17527658401 |
| diastolic heart failure | 147.17527658401 |
| american heart association | 143.75766327291 |
| acute decompensated heart failure | 143.51945164387 |
| new-onset heart failure | 141.21630632987 |
| heart failure society of america | 120.506594213 |
| incidence of heart failure | 118.88245834328 |
| heart disease | 115.51473789864 |
| ace inhibitors | 104.12993381006 |
| myocardial infarction | 97.141201813281 |
| symptomatic heart failure | 95.180225031078 |
| ventricular dysfunction | 91.927834917645 |
| nyha class ii | 89.843380196645 |
| advanced heart failure | 77.875396291055 |
| diagnosis of heart failure | 76.36157006205 |
| heart failure trial | 74.680896851249 |
| valsartan heart failure trial | 69.316207802652 |
| suspected heart failure | 68.030424883464 |
| clinical heart failure | 67.671396040077 |
| structural heart disease | 65.794994603193 |
| development of heart failure | 64.845532444825 |
| heart work | 61.502606079176 |
| risk factors | 56.78140354932 |
| increased risk | 55.130657644958 |
| systolic dysfunction | 53.149688412681 |
| treatment of heart failure | 52.64902149553 |
| heart failure patients | 52.488256746022 |
| history of heart failure | 49.058425528003 |
| heart failure outcomes | 48.828628936152 |
| prevention of heart failure | 48.828628936152 |
| common cause of heart failure | 46.217324350561 |
| diastolic dysfunction | 44.493513012808 |
| accf/aha stages of heart failure | 43.933256091005 |
| acute heart failure | 43.291703567625 |
| ventricular hypertrophy | 42.556750670457 |
| blood pressure | 40.912311036161 |
| ace inhibitor | 40.465445621929 |
| acute myocardial infarction | 39.157846511086 |
| valvular heart disease | 39.07778423469 |
| progression of heart failure | 38.937698145528 |
| reduced ejection fraction | 38.279943609919 |
| cardiac transplant | 38.088840897721 |
| nyha class | 37.168436488375 |
| systolic heart failure treatment | 36.624624147531 |
| clinical trial | 36.514252915594 |
| type of heart failure | 36.393324585865 |
| end-stage heart failure | 36.393324585865 |
| new heart failure | 36.393324585865 |
| chronic systolic heart failure | 36.280570898978 |
| heart failure hospitalizations | 35.304076582467 |
| heart failure information | 35.304076582467 |
| new york heart association | 35.161605961199 |
| chronic heart failure therapy | 34.119607961832 |
| heart failure exacerbations | 34.015212441732 |
| mild heart failure | 34.015212441732 |
| heart outcomes prevention evaluation | 32.550361330155 |
| overt heart failure | 32.422766222413 |
| refractory heart failure | 32.422766222413 |
| standard medical therapy | 32.220500574413 |
| comprehensive heart failure practice guideline | 30.512498229377 |
| established heart failure | 30.30410916161 |
| undiagnosed heart failure | 30.30410916161 |
| preserved ejection fraction | 29.847191914672 |
| primary symptoms of heart failure | 29.832302124903 |
| current symptoms of heart failure | 29.396302199663 |
| severe symptoms | 29.302732011878 |
| chronic congestive heart failure | 29.232377228144 |
| ventricular ejection fraction | 29.073272214158 |
| nyha class ii heart failure | 28.730557789481 |
| severe decompensated heart failure | 28.487192131714 |
| butler j | 27.817093114978 |
| functional cause of heart failure symptoms | 27.674153402284 |
| high risk | 27.565328822479 |
| severe chronic heart failure | 27.381589902864 |
| coronary disease | 27.162114335027 |
| nonischemic systolic heart failure | 27.139328065196 |
| functional class | 27.089969968019 |
| severe symptomatic heart failure | 25.624331641334 |
| advanced chronic heart failure | 25.481440613546 |
| non-ischemic systolic heart failure | 25.460562669705 |
| severe congestive heart failure | 25.289070095955 |
| renal function | 25.135581073296 |
| primary cause of heart failure | 24.870462797164 |
| stage c heart failure | 24.649903576842 |
| all-cause mortality | 24.578701598965 |
| pitt b | 23.905695622382 |
| valsartan heart failure trial investigators | 23.623333128789 |
| nyha class iii | 23.577076175429 |
| eur heart j | 23.377254482009 |
| long-term management of heart failure | 23.190179526877 |
| left ventricular systolic dysfunction | 22.710284630869 |
| ventricular pacing | 22.70333804263 |
| african american heart failure trial | 22.64064168927 |
| standard therapy | 22.62189070204 |
| left ventricular dysfunction | 22.095958211392 |
| family history of heart failure | 22.044116795314 |
| health burden of heart failure | 21.8669953659 |
| pulmonary artery pressure | 21.802122352441 |
| cardiovascular death | 21.65736770668 |
| myocardial ischemia | 21.502111138339 |
| randomized trial of patients | 21.281414946154 |
| population burden of heart failure | 21.265488388788 |
| high blood pressure | 20.387204864274 |
| borderline diastolic heart failure | 20.214544230179 |
| physical activity | 19.991995195515 |
| yusuf s | 19.817003712138 |
| different stages of heart failure | 19.759060825555 |
| african-american heart failure trial investigators | 19.74813326343 |
| early evidence of heart failure | 19.589389217353 |
| advanced end-stage heart failure | 19.500538833241 |
| clinical trials | 19.364606884933 |
| cases of incident heart failure | 19.215537915851 |
| modifiable risk factors | 19.096568395957 |
| heart catheterization | 19.078208021575 |
| cardiovascular disease | 18.95254888215 |
| heart failure incidence increases | 18.782564580814 |
| jacc heart fail | 18.673112610951 |
| treatment of preserved cardiac function heart failure | 18.550149920084 |
| palliative care | 18.44179994736 |
| total cost of heart failure | 18.265902668449 |
| nyha functional class iii heart failure patients | 18.217454040627 |
| medical therapy | 17.964918147966 |
| natural progression of heart failure | 17.882072954752 |
| emergency diagnosis of heart failure | 17.620725961188 |
| framingham heart study | 17.498080233577 |
| other risk factors | 17.278687223499 |
| heart murmur | 17.23910699358 |
| heart pumps | 17.23910699358 |
| randomized aldactone evaluation study | 17.087538022693 |
| clinical manifestations | 16.83639757978 |
| american college of cardiology/american heart association task force | 16.535658500992 |
| sinus rhythm | 16.413388798409 |
| rate control | 16.264836064977 |
| isosorbide dinitrate | 15.731731418229 |
| atrial fibrillation | 14.831171004269 |
| effect of enalapril | 14.810436756732 |
| reduced left ventricular ejection fractions | 14.67049846495 |
| clinical practice guidelines | 14.331909251528 |
| standard oral heart failure medications | 14.300957322253 |
| ventricular systolic dysfunction | 14.250752107168 |
| cardiac resynchronization-heart failure | 14.182398182435 |
| b-type natriuretic peptide | 14.104527674707 |
| seattle heart failure model | 14.084936415565 |
| heart outcomes prevention evaluation study investigators | 13.643378821151 |
| natriuretic peptide | 13.63463239761 |
| myocardial dysfunction | 13.339979404194 |
| large randomized controlled trial | 13.319992037631 |
| significant difference | 13.239003678587 |
| cardiac resynchronization | 13.127272139645 |
| randomized trial | 12.804343491775 |
| mcmurray jj | 12.728649475109 |
| symptomatic patients | 12.688455161287 |
| primary prevention | 12.638597791832 |
| weight gain | 12.358602863443 |
| pulmonary artery | 12.189889456761 |
| high-risk patients | 12.160801393263 |
| natriuretic peptide-guided therapy | 12.148130455988 |
| presence of risk factors | 12.135032696779 |
| mechanical circulatory support | 12.05693358307 |
| nonischemic cardiomyopathy | 11.988264044641 |
| svensson am | 11.741784511603 |
| ventricular function | 11.641674912519 |
| left ventricular ejection fraction | 11.525563868743 |
| asymptomatic patients | 11.500975876433 |
| functional capacity | 11.465313506452 |
| nhlbi heart failure clinical research network | 11.358108274759 |
| survival study | 11.233623397695 |
| icd implantation | 11.19016562612 |
| jessup m. stage b heart failure | 11.118430014839 |
| eplerenone post-acute myocardial infarction heart failure efficacy | 10.997210408437 |
| hospitalization rates | 10.954451150103 |
| global myocardial ischemia | 10.912809166167 |
| systolic blood pressure | 10.88520498932 |
| ventricular volume | 10.702456190343 |
| quality of life | 10.669676460234 |
| physical examination | 10.602356529148 |
| microvascular disease | 10.487221590056 |
| right heart catheterization | 10.4799301148 |
| specific causes | 10.392304845413 |
| bozkurt b | 10.392304845413 |
| trial investigators | 10.388739120117 |
| reduced risk | 10.261558002989 |
| controlled trial | 10.182919580087 |
| nyha functional classification | 10.142555229712 |
| clinical practice | 10.102415878263 |
| pulmonary disease | 10.019940278469 |
| cardiovascular mortality | 9.9312951847935 |
| inotropic agents | 9.7291971163912 |
| clinical outcomes | 9.6522804347375 |
| moderate symptoms | 9.6411410273358 |
| systolic blood pressure intervention trial | 9.6084651563334 |
| aldosterone antagonist | 9.603257618831 |
| study investigators | 9.5876942772625 |
| current guidelines | 9.5803106027242 |
| intravenous inotropic agents | 9.5374267604657 |
| acute coronary syndrome | 9.4985091341904 |
| american college of cardiology foundation | 9.3845904936053 |
| controlled trial of patients | 9.1337089660923 |
| american heart association statistics committee | 8.9787339517073 |
| coronary revascularization | 8.9720926873273 |
| cohn jn | 8.9442719099992 |
| other causes | 8.9442719099992 |
| induced coronary artery disease | 8.847853494422 |
| specific cause | 8.8186670410496 |
| disease control | 8.8186670410496 |
| circ heart fail | 8.7264615096001 |
| angiotensin receptor?neprilysin inhibitor | 8.7211839342619 |
| survival study investigators | 8.6332728113428 |
| wilson j | 8.6289073396314 |
| young j | 8.6289073396314 |
| lindenfeld j | 8.6289073396314 |
| consensus trial study group | 8.5920924788324 |
| symptomatic nyha class ii | 8.5915760184806 |
| ace inhibitor therapy | 8.5800543746011 |
| systemic disease | 8.5291344178582 |
| effect of carvedilol | 8.5242951907087 |
| krishnaswamy p | 8.4852813742386 |
| cardiovascular disease hospitalization | 8.4455351182242 |
| low cardiac output | 8.4200214932682 |
| third heart sound | 8.4078800764062 |
| initial laboratory evaluation | 8.3925789638182 |
| evaluation of patients | 8.3725700160278 |
| casey de jr | 8.2985253256109 |
| randomised trial | 8.1812469784701 |
| cardiac-resynchronization therapy | 8.1739324901763 |
| usual care | 8.1221727394757 |
| adverse changes | 8.1072009288422 |
| reduced mortality | 8.0770059874436 |
| ischemic cardiomyopathy | 7.9921760297609 |
| angiotensin-converting enzyme | 7.9774438454175 |
| lee kl | 7.8964440777149 |
| champion trial study group | 7.8789835426777 |
| 6-minute walk test | 7.845962916071 |
| haarbo j | 7.7970979610547 |
| neaton j | 7.7970979610547 |
| pogue j | 7.7970979610547 |
| emberson j | 7.7970979610547 |
| bosch j | 7.7970979610547 |
| mccord j | 7.7970979610547 |
| gong j | 7.7970979610547 |
| gallagher j | 7.7970979610547 |
| mathew j | 7.7970979610547 |
| care of patients | 7.7844093950776 |
| randomized aldactone evaluation study investigators | 7.7057858141598 |
| poor functional status | 7.5438910962342 |
| angiotensin receptor?neprilysin inhibitors | 7.5417066766768 |
| right ventricular function | 7.5395190889965 |
| clinical guidelines | 7.5352689577953 |
| implantable pulmonary artery pressure | 7.5053420380578 |
| cardiomems heart sensor | 7.490569582348 |
| left ventricular hypertrophy | 7.4659422745248 |
| cardiac resynchronization therapy | 7.461797978668 |
| acute pulmonary disease | 7.4527789849152 |
| glycemic control | 7.4448388728168 |
| randomized trial danish | 7.377854493525 |
| american college of cardiology foundation/american heart association task force | 7.3615515350663 |
| other risk factor | 7.3557314102613 |
| 20,985 patients | 7.3484692283495 |
| swedberg k | 7.3484692283495 |
| blood volume | 7.3256830029694 |
| first hospitalization | 7.3256830029694 |
| primary risk factors | 7.2867046089153 |
| inhibitor ivabradine trial | 7.2716336769238 |
| renal disease | 7.2560172494525 |
| functional class guides treatment | 7.2225756445557 |
| quality of care | 7.2217462736946 |
| observational study | 7.1407419177511 |
| zannad f | 7.1352426900163 |
| subset of patients | 7.1352426900163 |
| cardiovascular events | 7.1131176401557 |
| medical history | 7.0851677179898 |
| clinical studies | 7.0568830507494 |
| disease progression | 6.9009799013736 |
| advanced disease | 6.9009799013736 |
| volume overload | 6.8795812565008 |
| natriuretic peptide levels | 6.7807496594118 |
| loop diuretics | 6.700737917669 |
| clinical status | 6.673987930963 |
| effects of treatment | 6.6706214794855 |
| ventricular size | 6.6604914252356 |
| danish study | 6.6452091262532 |
| implantable cardioverter-defibrillator | 6.6400915182019 |
| angiotensin-receptor blockers | 6.6400915182019 |
| kazanegra r | 6.6195018392937 |
| prophylactic implantation | 6.6195018392937 |
| boineau r | 6.6195018392937 |
| latini r | 6.6195018392937 |
| outcomes of patients | 6.5934915059146 |
| range of risk factor levels | 6.558071028175 |
| american college of cardiology | 6.5412422314049 |
| effects of candesartan | 6.4474195909412 |
| usual clinical care | 6.3802363071573 |
| major risk factors | 6.3655227986524 |
| miracle icd trial | 6.3547610473256 |
| history of hospitalization | 6.3442275806434 |
| adverse effects | 6.3442275806434 |
| cannom ds | 6.3442275806434 |
| cardiac insufficiency bisoprolol study ii | 6.3179627563086 |
| multicenter insync icd randomized clinical evaluation | 6.3095633402878 |
| relative risk | 6.3086842910598 |
| lifetime risk | 6.3086842910598 |
| risk score | 6.3086842910598 |
| atherosclerosis risk | 6.3086842910598 |
| influence risk | 6.3086842910598 |
| accf/aha guideline | 6.2926925672916 |
| functional capacity of patients | 6.2273448933373 |
| left-ventricular ejection fraction | 6.2133136519014 |
| accf/aha guidelines | 6.1771812387753 |
| subjective symptoms | 6.160140576482 |
| serum digoxin levels | 6.1273116840957 |
| klein h | 6.1256286272176 |
| renal insufficiency | 6.1256286272176 |
| effect of digoxin | 6.1015588940837 |
| modification of risk factors | 6.0675163483893 |
| other patients | 6.0615465140299 |
| ventricular dyssynchrony | 6.0184333968691 |
| ventricular arrhythmias | 6.0184333968691 |
| ventricular enlargement | 6.0184333968691 |
| stevenson lw | 6 |
| shortness of breath | 6 |
| such cardiovascular risk factors | 5.9621371715169 |
| valvular disease | 5.957892135529 |
| solvd investigators | 5.9436557324017 |
| val-heft investigators | 5.9436557324017 |
| charm investigators | 5.9436557324017 |
| term gheart failure h | 5.9368741417647 |
| clinical syndrome | 5.9341076602399 |
| dietary sodium restriction | 5.9191344907092 |
| controlled clinical trials | 5.8878964084292 |
| cardiogenic shock | 5.8856619127654 |
| other mechanisms | 5.8856619127654 |
| previous myocardial infarction | 5.8653533983426 |
| other adverse effects | 5.8601559088987 |
| elevated systemic blood pressure | 5.8538734383683 |
| significant differences | 5.8259012604879 |
| oral diuretic therapy | 5.8249031191339 |
| monitoring of pressure | 5.8106700157786 |
| myocardial remodeling | 5.7991674783197 |
| myocardial structure | 5.7991674783197 |
| cardiovascular outcomes | 5.7850152170382 |
| j card fail | 5.7714994741381 |
| exercise capacity | 5.7326567532262 |
| symptomatic management | 5.7326567532262 |
| champion trial investigators | 5.717797486992 |
| harrison a | 5.7005397655436 |
| krum h | 5.7005397655436 |
| rawshani a | 5.7005397655436 |
| recognized risk factors | 5.6710361016125 |
| nonmodifiable risk factors | 5.6710361016125 |
| intensive blood pressure | 5.6586941766333 |
| low doses | 5.5663153674275 |
| packer m | 5.5663153674275 |
| rates of hyperkalemia | 5.5663153674275 |
| jessup m | 5.5663153674275 |
| important adverse effects | 5.547933582892 |
| daily pulmonary artery pressure readings | 5.5321413028549 |
| cardiac toxicity | 5.5193380421438 |
| cardiac output | 5.5193380421438 |
| nonfatal myocardial infarction | 5.4820834359262 |
| rates of hospitalization | 5.4772255750517 |
| charm-preserved trial | 5.4711295994695 |
| charm-alternative trial | 5.4711295994695 |
| cardiac pump function | 5.442323265122 |
| non-ischemic cardiomyopathy treatment evaluation | 5.438910834863 |
| symptoms of volume overload | 5.4146047111091 |
| advanced therapy | 5.3787500669746 |
| large population study | 5.3481384667782 |
| masson s | 5.3446902355676 |
| barlera s | 5.3446902355676 |
| madit-crt trial investigators | 5.3441695264733 |
| prospective randomized cumulative survival study group | 5.3249941204811 |
| gerdes am | 5.3049500053196 |
| kucharska-newton am | 5.3049500053196 |
| significant effect | 5.3049500053196 |
| emphasis-hf study group | 5.2974318574102 |
| held p | 5.26429605181 |
| jourdain p | 5.26429605181 |
| magnetic resonance imaging | 5.2414827884178 |
| myocardial sarcomere | 5.2401393526787 |
| clinical characteristics | 5.2226777991727 |
| clinical benefit | 5.2226777991727 |
| clinical assessment | 5.2226777991727 |
| ventricular noncompaction cardiomyopathy results | 5.200849059796 |
| optimal medical therapy | 5.1893987221281 |
| mild symptoms | 5.1800401282227 |
| functional status | 5.1800401282227 |
| blood tests | 5.1800401282227 |
| weight monitoring | 5.1800401282227 |
| hypomagnesemia increase risk | 5.1660198496359 |
| sudden death | 5.1510191538028 |
| cardiac muscle | 5.1363228010461 |
| cardiac structure | 5.1363228010461 |
| digoxin dose | 5.0914597900437 |
| ventricular dysfunction delays onset | 5.0761464007087 |
| left-ventricular systolic function | 5.0719730249202 |
| multinational study investigators | 5.0657970191009 |
| multicenter automatic defibrillator implantation trial ii investigators | 5.0514818398486 |
| elderly study | 5.0492670327448 |
| effects of enalapril | 5.0453784915223 |
| maladaptive ventricular hypertrophy | 5.0063266198115 |
| enalapril group | 4.9737947036147 |
| high risk of re-admission | 4.9241689779833 |
| patient's clinical status | 4.9027522910779 |
| randomised trial of losartan | 4.8760319739572 |
| quality measures | 4.8645985581956 |
| fluid restriction | 4.8645985581956 |
| therapy changes | 4.8602493374348 |
| drug therapy | 4.8602493374348 |
| randomised placebo-controlled study | 4.8490562872798 |
| increase exercise capacity | 4.8465663976689 |
| ace inhibitor ramipril | 4.8409406455445 |
| practice guidelines | 4.8339055525626 |
| diabetes care | 4.8294728055328 |
| independent risk factor | 4.8284476525076 |
| absence of symptoms | 4.8205705136679 |
| loop diuretic | 4.8205705136679 |
| refractory symptoms | 4.8205705136679 |
| pressure overload | 4.8026164940938 |
| other factors | 4.7867398586908 |
| sprint research study group | 4.7637250806784 |
| disease process | 4.7381372205376 |
| reduced diastolic | 4.7381372205376 |
| lung disease | 4.7381372205376 |
| clinical suggestions | 4.7192221235411 |
| clinical suspicion | 4.7192221235411 |
| african american patients | 4.7170518987602 |
| large double-blind trial | 4.6980201586465 |
| tognoni g | 4.6806946386414 |
| ischemic stroke | 4.6806946386414 |
| pulmonary causes of exercise limitation | 4.6806946386414 |
| sudden cardiac death | 4.6575419678526 |
| cardiac sarcoidosis | 4.6411915742122 |
| cardiac involvement | 4.6411915742122 |
| cardiac workload | 4.6411915742122 |
| cardiac valves | 4.6411915742122 |
| cardiac amyloidosis | 4.6411915742122 |
| cause of death | 4.6361821858297 |
| stars-bnp multicenter study | 4.6220442888931 |
| mild patients hospitalization | 4.6196709652247 |
| chronic atrial fibrillation | 4.6132323629156 |
| association of serum digoxin concentration | 4.5916055846449 |
| patient's nyha | 4.5825756949558 |
| k?ber l | 4.5590141139096 |
| effects of valsartan | 4.5590141139096 |
| combination of ace inhibitors | 4.5582562960338 |
| coronary angiography | 4.4860463436637 |
| metoprolol cr/xl randomised intervention trial | 4.4287921839498 |
| diabetes mellitus | 4.4267276788013 |
| inefficient ventricular contractile function | 4.4248034309981 |
| family history of cardiomyopathy | 4.4088173933227 |
| initial evaluation | 4.3679267425564 |
| prospective clinical trials | 4.3678557314809 |
| bnp levels | 4.3558771746929 |
| severity of symptoms | 4.3558771746929 |
| oral diuretic dose | 4.3440506352097 |
| other measures | 4.3253077270721 |
| american college of physicians | 4.3231140296575 |
| left-ventricular dysfunction | 4.2813902858562 |
| conduction abnormalities | 4.2813902858562 |
| givertz mm | 4.2813902858562 |
| maladaptive ventricular remodeling | 4.2513258303959 |
| prophylactic icd implantation | 4.2484406376281 |
| other important guidelines | 4.2448203141176 |
| right ventricular free wall | 4.2425598510497 |
| composite outcome | 4.2294850537623 |
| daubert jp | 4.2294850537623 |
| plasma digoxin levels | 4.2227675591121 |
| peripartum cardiomyopathy | 4.1824461364775 |
| other systemic disorders | 4.1689486953466 |
| cooperative north scandinavian enalapril survival study | 4.1683924274728 |
| oral furosemide therapy | 4.1633714773242 |
| recent observational study | 4.1623049031538 |
| prophylactic icd | 4.1408245796559 |
| objective measures of disease status | 4.1301657152851 |
| sinus rate | 4.1195342878142 |
| oxygen-rich blood | 4.1195342878142 |
| blood flow | 4.1195342878142 |
| blood counts | 4.1195342878142 |
| reduced rates | 4.090623489235 |
| Ã -blocker therapy | 4.0869662450882 |
| first-line therapy | 4.0869662450882 |
| appropriate therapy | 4.0869662450882 |
| evaluation of losartan | 4.0648138508249 |
| other important disorders | 4.0632051688874 |
| routine care | 4.0610863697379 |
| specific clinical indication | 4.0577694145156 |
| exercise training | 4.0536004644211 |
| role of palliative care | 4.0300296715324 |
| maisel as | 4 |
| gbridge therapy h | 3.9993486932656 |
| pressure-guided management of patients | 3.9654064565002 |
| serum levels of electrolytes | 3.9468319327726 |
| moss aj | 3.9359793425309 |
| staging system | 3.9359793425309 |
| ezekowitz ja | 3.9359793425309 |
| defibrillator implantation | 3.9359793425309 |
| fluid retention | 3.9359793425309 |
| patient information | 3.9359793425309 |
| controlled studies | 3.9359793425309 |
| gventricular dysfunction h | 3.9320768183025 |
| effect of diuretics | 3.8985489805273 |
| left bundle branch block | 3.8735854825302 |
| adverse events | 3.8729833462074 |
| pulmonary capillary wedge pressure | 3.8536671042695 |
| arni treatment | 3.8512851068431 |
| goal of treatment | 3.8512851068431 |
| early treatment | 3.8512851068431 |
| potential adverse effects | 3.8467222990467 |
| intolerable adverse effects | 3.8467222990467 |
| continuous intravenous inotropic agents | 3.8375885893579 |
| carvedilol post-infarct survival control | 3.8375885893579 |
| lo studio della streptochinasi nell finfarto miocardico-heart failure trial | 3.8349221943338 |
| laboratory evidence | 3.8067540958393 |
| peripheral vascular disease | 3.8027429028336 |
| houston-miller n | 3.7976578442319 |
| kagiyama n | 3.7976578442319 |
| freemantle n | 3.7976578442319 |
| heterogeneous study populations | 3.7817049765835 |
| ivabradine group | 3.7792667089114 |
| basic palliative care | 3.7666884513457 |
| palliative care addresses | 3.7666884513457 |
| aha stage c | 3.7578442412245 |
| specific type of cardiomyopathy | 3.7439265731403 |
| other treatment decisions | 3.7430197238696 |
| patient's daily weight | 3.7288210710016 |
| hall wj | 3.7224194364084 |
| qrs duration | 3.7224194364084 |
| bauman jg | 3.7224194364084 |
| muscular dystrophy | 3.7224194364084 |
| abraham wt | 3.7224194364084 |
| larson mg | 3.7224194364084 |
| pfeffer ma | 3.7224194364084 |
| incessant tachycardia | 3.7224194364084 |
| yancy cw | 3.7224194364084 |
| bourge rc | 3.7224194364084 |
| intravenous loop diuretics | 3.719046769829 |
| global mortality | 3.7126875376323 |
| adequate doses of ace inhibitors | 3.7098517435797 |
| population-based reykjavik study | 3.708192102729 |
| only therapy | 3.6929908877475 |
| ordinary physical activity | 3.6830484346607 |
| invasive evaluation | 3.6729739399065 |
| safety of exercise training | 3.6666352749723 |
| advanced stages | 3.6628415014847 |
| b-type natriuretic peptide assay | 3.6628415014847 |
| supervised exercise | 3.6628415014847 |
| a1c levels | 3.6628415014847 |
| other noninvasive imaging | 3.6590516533172 |
| effect of metoprolol cr/xl | 3.6529276674218 |
| european society of cardiology | 3.6467519140054 |
| direct myocardial toxin?it | 3.6231148419824 |
| increased mortality | 3.6161715709604 |
| regional dysfunction | 3.6002057436785 |
| sodium restriction | 3.6002057436785 |
| digoxin toxicity | 3.6002057436785 |
| serum level | 3.6002057436785 |
| controlled trials | 3.6002057436785 |
| inhibitor ramipril | 3.5840246342157 |
| angiotensin-converting-enzyme inhibitor | 3.5840246342157 |
| variety of patients | 3.5676213450082 |
| arrhythmogenic right ventricular dysplasia | 3.567553370247 |
| elevated total cholesterol levels | 3.5620857880302 |
| health care costs | 3.561271038656 |
| cardiovascular system | 3.5565588200778 |
| volume status | 3.5565588200778 |
| clinical slide set | 3.5447880909253 |
| ability of icd implantation | 3.5376050502214 |
| danish investigators | 3.5341188430494 |
| renal excretion of digoxin | 3.503082197055 |
| other medications | 3.4996355115806 |
| other à -blockers | 3.4996355115806 |
| other lifestyle changes | 3.4877505632064 |
| miracle icd | 3.4820045452271 |
| appropriate serum level of digoxin | 3.473041544387 |
| hemodynamically significant ventricular septal defects | 3.4683547086532 |
| felker gm | 3.4641016151377 |
| cigarette smoking | 3.4641016151377 |
| benjamin ej | 3.4641016151377 |
| granger cb | 3.4641016151377 |
| brown mw | 3.4641016151377 |
| family history | 3.4641016151377 |
| end-organ hypoperfusion | 3.4641016151377 |
| davis ce | 3.4641016151377 |
| few days | 3.4641016151377 |
| stable weight | 3.4641016151377 |
| united states | 3.4641016151377 |
| hiv infection | 3.4641016151377 |
| d fagostino r jr | 3.4519247197843 |
| first-line drug therapy | 3.4458199066465 |
| nondiabetic control group | 3.4312578792284 |
| other relevant pqrs quality measures | 3.4278736200193 |
| spironolactone group | 3.4149529703483 |
| collaborative care | 3.4149529703483 |
| guided care | 3.4149529703483 |
| decrease hospitalization | 3.4086580994025 |
| bundle branch block | 3.3967626591299 |
| effect of spironolactone | 3.3895612242702 |
| trabeculated myocardial architecture | 3.3863633634254 |
| aha stage | 3.3635856610149 |
| use of bnp | 3.3635856610149 |
| prophylactic defibrillator implantation | 3.3604214537127 |
| other performance measures | 3.3446807651574 |
| other tests | 3.3437015248821 |
| meta-analysis global group | 3.3285607270274 |
| cardiopulmonary exercise test | 3.3244690547396 |
| smith r | 3.3097509196469 |
| natriuretic peptides | 3.3097509196469 |
| genetic disorders | 3.3097509196469 |
| careful monitoring of serum potassium levels | 3.2957569692557 |
| severe cardiogenic shock | 3.2598444275496 |
| current measures | 3.2531531233956 |
| time-to-furosemide treatment | 3.2385318404644 |
| hospital admission rate | 3.2377408137211 |
| angiotensin-converting enzyme inhibitors | 3.2368032890054 |
| atrial arrhythmia | 3.2237097954706 |
| hospitalized patients | 3.2237097954706 |
| selected patients | 3.2237097954706 |
| natural history | 3.2237097954706 |
| elevated levels of low-density lipoprotein cholesterol | 3.2113286293254 |
| low high-density lipoprotein cholesterol levels | 3.2113286293254 |
| detrimental effect of sodium restriction | 3.2033666669598 |
| functional mitral regurgitation | 3.2031009475288 |
| cardiopulmonary exercise testing | 3.2031009475288 |
| obesity-related cardiomyopathy | 3.1779718278113 |
| dilated cardiomyopathy | 3.1779718278113 |
| tachycardia-induced cardiomyopathy | 3.1779718278113 |
| diabetic cardiomyopathy | 3.1779718278113 |
| eplerenone group | 3.1779718278113 |
| hypertrophic cardiomyopathy | 3.1779718278113 |
| ordinary physical activity results | 3.1616447614742 |
| prediction of survival | 3.1463462836458 |
| expected survival | 3.1463462836458 |
| survival advantage | 3.1463462836458 |
| meaningful survival | 3.1463462836458 |
| noninvasive imaging | 3.1301691601466 |
| long-term use | 3.1301691601466 |
| aborted cardiac arrest | 3.1231391134797 |
| smith al | 3.1054227990715 |
| structured cardiac rehabilitation program | 3.0918884056739 |
| high doses | 3.080070288241 |
| large multicenter | 3.080070288241 |
| nt-probnp levels | 3.080070288241 |
| thiazide diuretic | 3.080070288241 |
| electrolyte levels | 3.080070288241 |
| current aha guidelines | 3.0668124740328 |
| yancy c | 3.0628143136088 |
| other genetic disorders of iron metabolism | 3.0600833060707 |
| different types of care | 3.0569032462135 |
| elevated jugular venous pressure | 3.0400841363597 |
| systemic disorder | 3.0274001040351 |
| practice improvement | 3.0274001040351 |
| systemic diseases | 3.0274001040351 |
| iron overload | 3.0274001040351 |
| daily weight checks | 3.0261714988458 |
| iervasi g. thyroid replacement therapy | 3.0061164174793 |
| natriuretic peptide-based screening | 2.9937951655239 |
| observational studies | 2.9906975624424 |
| doukky r | 2.9906975624424 |
| segal r | 2.9906975624424 |
| quigg r | 2.9906975624424 |
| comenzo r | 2.9906975624424 |
| quality indicators | 2.9906975624424 |
| marchioli r | 2.9906975624424 |
| davies r | 2.9906975624424 |
| lieberman r | 2.9906975624424 |
| cody r | 2.9906975624424 |
| deo r | 2.9906975624424 |
| cremo r | 2.9906975624424 |
| amirnovin r | 2.9906975624424 |
| physical activities | 2.9718278662008 |
| physical exam | 2.9718278662008 |
| physical therapists | 2.9718278662008 |
| predictors of mortality | 2.9525917237372 |
| laboratory tests | 2.9428309563827 |
| such reversible cardiac conditions | 2.9390867394432 |
| hospital readmission rates | 2.9355985352441 |
| long-term inotropic infusion | 2.9279034960725 |
| specific structural abnormalities | 2.9279034960725 |
| physician quality reporting system | 2.9278526754426 |
| riegel b | 2.9129506302439 |
| history of angioedema | 2.9129506302439 |
| end-of-life management | 2.9129506302439 |
| olofsson b | 2.9129506302439 |
| increased bnp | 2.9129506302439 |
| levin b | 2.9129506302439 |
| eliasson b | 2.9129506302439 |
| symptom management | 2.9129506302439 |
| roniker b | 2.9129506302439 |
| significant data | 2.9129506302439 |
| wilkoff b | 2.9129506302439 |
| claggett b | 2.9129506302439 |
| diastolic relaxation | 2.9129506302439 |
| reduced hospitalizations | 2.8925076085191 |
| unexplained weight gain | 2.8844991406148 |
| angiotensin-receptor blocker valsartan | 2.8844991406148 |
| intensive hypertension control | 2.8844991406148 |
| lot of weight gain | 2.8844991406148 |
| angiotensin-converting-enzyme inhibitors | 2.882121417102 |
| acute exacerbations | 2.8716217110259 |
| placebo group | 2.8716217110259 |
| sacubitril?valsartan group | 2.8716217110259 |
| epicardial coronary arteries | 2.8536385282275 |
| thyroid-stimulating hormone levels | 2.8536385282275 |
| maggioni a | 2.8502698827718 |
| left ventricle | 2.8502698827718 |
| outpatient dose | 2.8284271247462 |
| routine use | 2.8284271247462 |
| ordinary activity | 2.8284271247462 |
| selective aldosterone blocker | 2.8210130123402 |
| combination of isosorbide dinitrate | 2.8077989890847 |
| taylor al | 2.8060662632967 |
| symptomatic bradycardia | 2.7831576837137 |
| diuretic effectiveness | 2.7831576837137 |
| lee ds | 2.7831576837137 |
| diuretic strategies | 2.7831576837137 |
| diuretic adjustments | 2.7831576837137 |
| Ã -blockers carvedilol | 2.7831576837137 |
| biomarker intensified treatment | 2.7578805125536 |
| overall mortality | 2.7476962050545 |
| structured aerobic exercise program | 2.746743631666 |
| liver function | 2.7355647997348 |
| rosengren a. glycaemic control | 2.7285232036427 |
| levy d | 2.7108060108295 |
| atrial abnormality | 2.7108060108295 |
| important characteristics | 2.7108060108295 |
| important organs | 2.7108060108295 |
| long-term safety | 2.7108060108295 |
| wide range of causes | 2.6960123091946 |
| nonvalvular atrial fibrillation | 2.6889452937027 |
| shift investigators | 2.6853496142827 |
| topcat investigators | 2.6853496142827 |
| paradigm-hf investigators | 2.6853496142827 |
| warcef investigators | 2.6853496142827 |
| gissi-hf investigators | 2.6853496142827 |
| hf-action investigators | 2.6853496142827 |
| hope investigators | 2.6853496142827 |
| acute dyspnea | 2.6723451177838 |
| formal exercise programs | 2.66716827534 |
| other shunts | 2.6591479484725 |
| le helloco a | 2.6571971456127 |
| elkayam u. peripartum cardiomyopathy | 2.6521704180372 |
| v-heft va cooperative studies group | 2.6379831394264 |
| tolerated dose | 2.632148025905 |
| significant reductions | 2.632148025905 |
| last dose | 2.632148025905 |
| sodium intake | 2.632148025905 |
| significant reduction | 2.632148025905 |
| angiotensin-receptor blocker | 2.632148025905 |
| elevated bnp | 2.632148025905 |
| current medications | 2.632148025905 |
| ann intern med | 2.6207413942089 |
| selective aldosterone antagonist | 2.6084654714896 |
| several consensus guidelines | 2.6043085235871 |
| heterogeneous group of outpatients | 2.5958936998277 |
| hemodynamic monitoring | 2.5900200641113 |
| cushman m | 2.5900200641113 |
| baggett c | 2.5755095769014 |
| avezum a | 2.5755095769014 |
| perez a | 2.5755095769014 |
| rapezzi c | 2.5755095769014 |
| chavelas c | 2.5755095769014 |
| kiran a | 2.5755095769014 |
| dan a | 2.5755095769014 |
| barth c | 2.5755095769014 |
| dyer a | 2.5755095769014 |
| yilmaz a | 2.5755095769014 |
| shi h | 2.5755095769014 |
| castaigne a | 2.5755095769014 |
| mangla a | 2.5755095769014 |
| henrick a | 2.5755095769014 |
| dubost-brama a | 2.5755095769014 |
| laupacis a | 2.5755095769014 |
| kopp a | 2.5755095769014 |
| ukena c | 2.5755095769014 |
| avogaro a | 2.5755095769014 |
| conlon c | 2.5755095769014 |
| kadish a | 2.5755095769014 |
| glomerular filtration rate | 2.5697965868507 |
| tolerated dose of à -blockers | 2.5697965868507 |
| intravenous bolus | 2.5457298950218 |
| definitive evidence | 2.5457298950218 |
| strong evidence | 2.5457298950218 |
| aldosterone antagonists | 2.5457298950218 |
| causative factors | 2.5457298950218 |
| digitalis investigation group | 2.5454319088428 |
| short-term symptomatic benefits | 2.5423029068338 |
| used loop diuretics | 2.5132368765511 |
| parasuraman s. glycemic control | 2.5020668097181 |
| in-hospital mortality | 2.4828237961984 |
| physician quality reporting initiative?that clinicians | 2.4754341287137 |
| overt cardiogenic shock | 2.4662120743305 |
| rapid b-natriuretic peptide assay | 2.4494897427832 |
| advanced therapies | 2.4494897427832 |
| primary outcome | 2.4494897427832 |
| kavalieratos d | 2.4494897427832 |
| logeart d | 2.4494897427832 |
| same population | 2.4494897427832 |
| lifestyle modifications | 2.4494897427832 |
| aguilar d | 2.4494897427832 |
| johnstone d | 2.4494897427832 |
| ettehad d | 2.4494897427832 |
| mozaffarian d | 2.4494897427832 |
| gras d | 2.4494897427832 |
| valvular abnormalities | 2.4322992790978 |
| joshua-gotlib s | 2.4147364027664 |
| franz?n s | 2.4147364027664 |
| kuroda s | 2.4147364027664 |
| homma s | 2.4147364027664 |
| ziesche s | 2.4147364027664 |
| gudbj?rnsdottir s | 2.4147364027664 |
| non?left bundle branch block pattern | 2.3924623977026 |
| carson p | 2.3784142300054 |
| clopton p | 2.3784142300054 |
| severe comorbidities | 2.3784142300054 |
| maximum dose | 2.3784142300054 |
| beyne p | 2.3784142300054 |
| severe signs | 2.3784142300054 |
| sleight p | 2.3784142300054 |
| gueffet p | 2.3784142300054 |
| use age | 2.3784142300054 |
| elliott p | 2.3784142300054 |
| mohacsi p | 2.3784142300054 |
| afterload-reducing agents | 2.3784142300054 |
| duc p | 2.3784142300054 |
| dennison himmelfarb c | 2.3672935308725 |
| terms gcardiomyopathy h | 2.3672935308725 |
| dei cas a | 2.3672935308725 |
| systemic lupus erythematosus | 2.3490100793233 |
| continuous intravenous administration | 2.3490100793233 |
| multicenter guide-it | 2.3403473193207 |
| komajda m | 2.3403473193207 |
| lenski m | 2.3403473193207 |
| miftaraj m | 2.3403473193207 |
| diagnostic tests | 2.3403473193207 |
| lind m | 2.3403473193207 |
| b?hm m | 2.3403473193207 |
| fiuzat m | 2.3403473193207 |
| olsson m | 2.3403473193207 |
| Ã -blocker carvedilol | 2.3403473193207 |
| ledwidge m | 2.3403473193207 |
| semigran m | 2.3403473193207 |
| electrocardiographic monitoring | 2.3403473193207 |
| hospital-level 30-day mortality | 2.3101522238684 |
| robust predictor of mortality | 2.3101522238684 |
| oral anticoagulants | 2.3003266337912 |
| nma/pcna guideline | 2.3003266337912 |
| oral torsemide | 2.3003266337912 |
| patient's outpatient | 2.3003266337912 |
| guiding evidence | 2.3003266337912 |
| conflicting evidence | 2.3003266337912 |
| optimal therapeutic range | 2.2894284851067 |
| replacement device | 2.2795070569548 |
| maisel a. utility | 2.2449240966188 |
| hood wb jr | 2.2390395117024 |
| several medications | 2.2133638394006 |
| subjective assessment | 2.2133638394006 |
| modification of hypertension | 2.2133638394006 |
| martinez f | 2.2133638394006 |
| healthcare research | 2.2133638394006 |
| 2-lb increase | 2.2133638394006 |
| avery e | 2.2133638394006 |
| 5-lb increase | 2.2133638394006 |
| diverse range | 2.2133638394006 |
| impact of diabetes | 2.2133638394006 |
| general population | 2.2133638394006 |
| patient's subjective experience | 2.1955146386099 |
| stroke statistics subcommittee | 2.1822472719434 |
| role of lifestyle modifications | 2.1822472719434 |
| deswal a. relationship of hemoglobin | 2.1810154653305 |
| nonsudden death | 2.165736770668 |
| hemodynamic overload | 2.1406951429281 |
| thiazide diuretics | 2.1406951429281 |
| tobacco use screening | 2.1398263878673 |
| many genetic cardiomyopathies | 2.1398263878673 |
| alternative imaging methods | 2.1398263878673 |
| ojamaa k. thyroid hormone | 2.1351847961967 |
| serious health condition | 2.1169328630255 |
| thorgeirsson g | 2.1147425268811 |
| thabut g | 2.1147425268811 |
| meurers g | 2.1147425268811 |
| johnson g | 2.1147425268811 |
| dagenais g | 2.1147425268811 |
| jondeau g | 2.1147425268811 |
| ginn g | 2.1147425268811 |
| noninvasive computed tomographic angiography | 2.1039790110173 |
| author thanks lee r. goldberg | 2.0827594879848 |
| effective gsliding h regimen | 2.0812192439376 |
| djousse l | 2.0597671439071 |
| hood wb | 2.0597671439071 |
| tavazzi l | 2.0597671439071 |
| long-term benefit | 2.0597671439071 |
| damman k | 2.0597671439071 |
| rapid measurement | 2.0597671439071 |
| matsushita k | 2.0597671439071 |
| primary prophylaxis | 2.0597671439071 |
| lenert l | 2.0597671439071 |
| ramasubbu k | 2.0597671439071 |
| malmberg k | 2.0597671439071 |
| additional medications | 2.0597671439071 |
| kappenberger l | 2.0597671439071 |
| angelici l | 2.0597671439071 |
| ferdinand k | 2.0597671439071 |
| fibrofatty replacement | 2.0597671439071 |
| videb?k l | 2.0597671439071 |
| 2-dimensional doppler echocardiography | 2.0396489026555 |
| two-dimensional doppler echocardiography | 2.0396489026555 |
| additional diagnostic testing | 2.0396489026555 |
| prognostic value of changes | 2.0396489026555 |
| raimondi e | 2 |
| korup e | 2 |
| chemotherapeutic agents trastuzumab | 2 |
| total distance | 2 |
| tallon e | 2 |
| funck f | 2 |
| suspected cases | 2 |
| long-standing untreated hypertension | 2 |
| daubert jc | 2 |
| mahfoud f | 2 |
| million persons | 2 |
| 7.5 mg | 2 |
| beauvais f | 2 |
| donal e | 2 |
| million hospital discharges | 2 |
| hemoglobin a1c | 2 |
| erdmann e | 2 |
| o fconnell e | 2 |
| prospective comparison of arni | 2 |
| home health staff | 1.9786024464679 |
| lindenfeld ja | 1.9679896712654 |
| prognostic information | 1.9679896712654 |
| high-risk populations | 1.9679896712654 |
| combination of hydralazine | 1.9679896712654 |
| downloadable guideline algorithm | 1.9559811771959 |
| wall-motion abnormalities | 1.9343364202677 |
| thune jj | 1.9343364202677 |
| active ischemia | 1.9343364202677 |
| mamdani mm | 1.9343364202677 |
| redfield mm | 1.9343364202677 |
| patient's circumstances | 1.9343364202677 |
| teerlink jr | 1.9343364202677 |
| scheinman mm | 1.9343364202677 |
| glucose abnormalities | 1.9343364202677 |
| colvin mm | 1.9343364202677 |
| excess iron deposition | 1.9063685859939 |
| long-acting metoprolol succinate | 1.9063685859939 |
| implantable cardioversion defibrillation | 1.9063685859939 |
| sustained efficacy | 1.8612097182042 |
| goldberg lr | 1.8612097182042 |
| alcohol consumption | 1.8612097182042 |
| vago t | 1.8612097182042 |
| efficacy of icds | 1.8612097182042 |
| many areas | 1.8612097182042 |
| absence of arrhythmia | 1.8612097182042 |
| remme wj | 1.8612097182042 |
| continuous infusion | 1.8612097182042 |
| social support | 1.8612097182042 |
| direct toxicity | 1.8612097182042 |
| new agent | 1.8612097182042 |
| first calls | 1.8612097182042 |
| hardarson t | 1.8612097182042 |
| routine anticoagulation | 1.8612097182042 |
| definitive therapies | 1.8612097182042 |
| major hemorrhage | 1.8612097182042 |
| aspelund t | 1.8612097182042 |
| yamaguchi t | 1.8612097182042 |
| objective predictors | 1.8612097182042 |
| callender t | 1.8612097182042 |
| common precursor molecule | 1.8493111942973 |
| composite end point | 1.8493111942973 |
| regular measurement of electrolytes | 1.8171205928321 |
| improved safety profiles | 1.8171205928321 |
| van veldhuisen dj | 1.7817974362807 |
| early postpartum period | 1.7817974362807 |
| complete follow-up results | 1.7817974362807 |
| several regulatory agencies | 1.7817974362807 |
| review of animal models | 1.7817974362807 |
| composite of time | 1.7782794100389 |
| common questions | 1.7782794100389 |
| preventable syndrome | 1.7782794100389 |
| frequent hospitalizations | 1.7782794100389 |
| combination of sacubitril | 1.7782794100389 |
| heart-failure events | 1.7782794100389 |
| recurrent hospitalizations | 1.7782794100389 |
| neyra ja | 1.7782794100389 |
| curtis jp | 1.7782794100389 |
| biventricular pacing | 1.7782794100389 |
| boehmer jp | 1.7782794100389 |
| coats aj | 1.7782794100389 |
| cowley aj | 1.7782794100389 |
| peripheral edema | 1.7320508075689 |
| same benefits | 1.7320508075689 |
| strong muscle | 1.7320508075689 |
| collins kj | 1.7320508075689 |
| cushman wc | 1.7320508075689 |
| aortic regurgitation | 1.7320508075689 |
| maggioni ap | 1.7320508075689 |
| levy wc | 1.7320508075689 |
| remme w | 1.7320508075689 |
| wang y | 1.7320508075689 |
| stable outpatients | 1.7320508075689 |
| peak oxygen consumption | 1.6983813295649 |
| paroxysmal nocturnal dyspnea | 1.6983813295649 |
| last trimester of pregnancy | 1.6983813295649 |
| giant cell myocarditis | 1.6983813295649 |
| shantsila e. anticoagulation | 1.6983813295649 |
| katus ha | 1.6817928305074 |
| franzosi mg | 1.6817928305074 |
| whellan dj | 1.6817928305074 |
| evans jc | 1.6817928305074 |
| sound waves | 1.6817928305074 |
| freudenberger rs | 1.6817928305074 |
| one meta-analysis | 1.6817928305074 |
| stress testing | 1.6817928305074 |
| increases regression | 1.6817928305074 |
| wilber dj | 1.6817928305074 |
| muscular dystrophies | 1.6817928305074 |
| white persons | 1.6817928305074 |
| episodic arrhythmia | 1.6817928305074 |
| ellis sj | 1.6817928305074 |
| desai as | 1.6817928305074 |
| packer dl | 1.6817928305074 |
| qrs prolongation | 1.6817928305074 |
| nielsen jc | 1.6817928305074 |
| tycon le | 1.6817928305074 |
| systematic review | 1.6817928305074 |
| rare disorder | 1.6817928305074 |
| klein hu | 1.6817928305074 |
| major problem | 1.6817928305074 |
| beanlands rs | 1.6817928305074 |
| unpredictable exacerbations | 1.6817928305074 |
| elimination of tachycardia | 1.6817928305074 |
| slight limitation | 1.6817928305074 |
| poor prognosis | 1.6817928305074 |
| many parts | 1.6817928305074 |
| black persons | 1.6817928305074 |
| rheumatologic diseases | 1.6817928305074 |
| ha ac | 1.6817928305074 |
| cleland jg | 1.6817928305074 |
| marked limitation | 1.6817928305074 |
| wall thickness | 1.6817928305074 |
| serial echocardiography | 1.6817928305074 |
| enrollment goal | 1.6817928305074 |
| drink alcohol | 1.6817928305074 |
| heritable disorder | 1.6817928305074 |
| vasan rs | 1.6817928305074 |
| african americans | 1.6817928305074 |
| ambrosius wt | 1.6817928305074 |
| cochrane database syst rev | 1.6817928305074 |
| wood ma | 1.6817928305074 |
| dietary recommendations | 1.6817928305074 |
| million people | 1.6817928305074 |
| keteyian sj | 1.6817928305074 |
| select therapies | 1.6817928305074 |
| ellison rc | 1.6817928305074 |
| inflammatory diseases | 1.6817928305074 |
| suitable alternative | 1.6817928305074 |
| pocock sj | 1.6817928305074 |
| insoluble fibrillar proteins | 1.5874010519682 |
| myocyte adipose accumulation | 1.5874010519682 |
| autosomal dominant mutations | 1.5874010519682 |
| complex psychosocial issues | 1.5874010519682 |
| emdin ca | 1.5650845800733 |
| fitzpatrick ap | 1.5650845800733 |
| low-sodium diet | 1.5650845800733 |
| n-terminal pro?b | 1.5650845800733 |
| lower-extremity edema | 1.5650845800733 |
| n-terminal pro-brain | 1.5650845800733 |
| das sr | 1.5650845800733 |
| rathore ss | 1.5650845800733 |
| bristow mr | 1.5650845800733 |
| anstrom kj | 1.5650845800733 |
| former condition | 1.5650845800733 |
| avery cl | 1.5650845800733 |
| collins sp | 1.5650845800733 |
| decrease afterload | 1.5650845800733 |
| jensen dn | 1.5650845800733 |
| audrey wu | 1.5650845800733 |
| hollander je | 1.5650845800733 |
| costanzo mr | 1.5650845800733 |
| nery pb | 1.5650845800733 |
| khan ss | 1.5650845800733 |
| gudnason v | 1.5650845800733 |
| ariti ca | 1.5650845800733 |
| dr. wu | 1.5650845800733 |
| shinbane js | 1.5650845800733 |
| loehr lr | 1.5650845800733 |
| wang tj | 1.5650845800733 |
| second calls | 1.5650845800733 |
| professional roles | 1.5650845800733 |
| nowak rm | 1.5650845800733 |
| matsue y | 1.5650845800733 |
| emergency department | 1.5650845800733 |
| developed areas | 1.5650845800733 |
| anderson kp | 1.5650845800733 |
| rizkala ar | 1.5650845800733 |
| juurlink dn | 1.5650845800733 |
| ann arbor | 1.5650845800733 |
| nonpharmacologic interventions | 1.5650845800733 |
| specialized interventions | 1.5650845800733 |
| cavity size | 1.5650845800733 |
| leon ar | 1.5650845800733 |
| short-term basis | 1.5650845800733 |
| borer js | 1.5650845800733 |
| carey rm | 1.5650845800733 |
| previous version | 1.5650845800733 |
| enough data | 1.5650845800733 |
| goldsmith sr | 1.5650845800733 |
| hereditary hemochromatosis | 1.5650845800733 |
| intracerebral hemorrhage | 1.5650845800733 |
| overall frailty | 1.5650845800733 |
| variety of antigens | 1.5650845800733 |
| intracardiac device | 1.5650845800733 |
| impact of obesity | 1.5650845800733 |
| wilson pw | 1.5650845800733 |
| nutritional supplements | 1.5650845800733 |
| hypersensitivity myocarditis | 1.5650845800733 |
| poole je | 1.5650845800733 |
| hereditary anemias | 1.5650845800733 |
| bekelman db | 1.5650845800733 |
| aortic stenosis | 1.5650845800733 |
| zareba w | 1.5650845800733 |
| ibrahim z | 1.5650845800733 |
| young jb | 1.5650845800733 |
| mark db | 1.5650845800733 |
| compared hydralazine | 1.5650845800733 |
| plasma brain | 1.5650845800733 |
| low-salt diet | 1.5650845800733 |
| anderson sg | 1.5650845800733 |
| various organs | 1.5650845800733 |
| nutritional deficiencies | 1.5650845800733 |
| arany z | 1.5650845800733 |
| martinez fa | 1.5650845800733 |
| professional organizations | 1.5650845800733 |
| adamson pb | 1.5650845800733 |
| kutyifa v | 1.5650845800733 |
| allergic reaction | 1.4142135623731 |
| michelson el | 1.4142135623731 |
| bonow ro | 1.4142135623731 |
| vision disturbances | 1.4142135623731 |
| leip ep | 1.4142135623731 |
| gottlieb so | 1.4142135623731 |
| cropp ab | 1.4142135623731 |
| cool extremities | 1.4142135623731 |
| sinoatrial node | 1.4142135623731 |
| walsh cr | 1.4142135623731 |
| painful gynecomastia | 1.4142135623731 |
| krumholz hm | 1.4142135623731 |
| arnold jm | 1.4142135623731 |
| urgent-care setting | 1.4142135623731 |
| unrealistic expectations | 1.4142135623731 |
| medicaid services | 1.4142135623731 |
| fowler mb | 1.4142135623731 |
| angiotensin-neprilysin inhibition | 1.4142135623731 |
| mayo clinic | 1.4142135623731 |
| congenital lesions | 1.4142135623731 |
| aronow ws | 1.4142135623731 |
| bates jt | 1.4142135623731 |
| painless procedure | 1.4142135623731 |
| past decade | 1.4142135623731 |
| estes na | 1.4142135623731 |
| collado fm | 1.4142135623731 |
| zhang zm | 1.4142135623731 |
| expert opinion | 1.4142135623731 |
| chiuve se | 1.4142135623731 |
| heavy toll | 1.4142135623731 |
| hazard ratio | 1.4142135623731 |
| thompson jl | 1.4142135623731 |
| effort intolerance | 1.4142135623731 |
| influenza immunization | 1.4142135623731 |
| thiamine deficiency | 1.4142135623731 |
| predetermined threshold | 1.4142135623731 |
| predicted distances | 1.4142135623731 |
| industrialized countries | 1.4142135623731 |
| university of michigan | 1.4142135623731 |
| assmann sf | 1.4142135623731 |
| ellenbogen ka | 1.4142135623731 |
| smoke cigarettes | 1.4142135623731 |
| progressive weakness | 1.4142135623731 |
| gelfman lp | 1.4142135623731 |
| linker dt | 1.4142135623731 |
| bonus payments | 1.4142135623731 |
| pullicino pm | 1.4142135623731 |
| bardy gh | 1.4142135623731 |
| maurer ms | 1.4142135623731 |
| lefkowitz mp | 1.4142135623731 |
| endomyocardial biopsy | 1.4142135623731 |
| gruppo italiano | 1.4142135623731 |
| noncaseating granulomata | 1.4142135623731 |
| ikejiani dz | 1.4142135623731 |
| place chairs | 1.4142135623731 |
| sex-specific equations | 1.4142135623731 |
| repeated transfusions | 1.4142135623731 |
| viable myocardium | 1.4142135623731 |
| reasonable expectation | 1.4142135623731 |
| soliman ez | 1.4142135623731 |
| loeb hs | 1.4142135623731 |
| daniels lb | 1.4142135623731 |
| swollen feet | 1.4142135623731 |
| radionuclide ventriculography | 1.4142135623731 |
| fconnor cm | 1.4142135623731 |
| bull da | 1.4142135623731 |
| euthyroid state | 1.4142135623731 |
| albert nm | 1.4142135623731 |
| speed of absorption | 1.4142135623731 |
| poulin mf | 1.4142135623731 |
| attractive possibility | 1.4142135623731 |
| sutradhar sc | 1.4142135623731 |
| characteristic presentation | 1.4142135623731 |
| shown promise | 1.4142135623731 |
| drazner mh | 1.4142135623731 |
| straight line | 1.4142135623731 |
| blaha mj | 1.4142135623731 |
| mentz rj | 1.4142135623731 |
| cleavage products | 1.4142135623731 |
| journal circulation | 1.4142135623731 |
| voors aa | 1.4142135623731 |
| adams kf | 1.4142135623731 |
| cooper ls | 1.4142135623731 |
| extent of disability | 1.4142135623731 |
| abdominal bloating | 1.4142135623731 |
| chang pp | 1.4142135623731 |
| austin pc | 1.4142135623731 |
| healthy adults | 1.4142135623731 |
| tool kit | 1.4142135623731 |
| dao q | 1.4142135623731 |
| squire ib | 1.4142135623731 |
| prior chemotherapy | 1.4142135623731 |
| whelton pk | 1.4142135623731 |
| nichols ga | 1.4142135623731 |
| dargie hj | 1.4142135623731 |
| birnie dh | 1.4142135623731 |
| future priorities | 1.4142135623731 |
| morrison lk | 1.4142135623731 |
| educational material | 1.4142135623731 |
| self-care guide | 1.4142135623731 |
| lip gy | 1.4142135623731 |
| striated muscles | 1.4142135623731 |
| anorexia nervosa | 1.4142135623731 |
| executive summary | 1.4142135623731 |
| obvious explanation | 1.4142135623731 |
| anker sd | 1.4142135623731 |
| neurohormonal activation | 1.4142135623731 |
| j.jacc .2016.03.605 | 1 |
| .0 b013e31829e8807 | 1 |
| 1.2 ng/ml | 1 |
| 0.8 ng/ml | 1 |
| 2.5 times | 1 |
頻出語ITC103
| 抽出語 | 出現回数 | 抽出語 | 出現回数 | 抽出語 | 出現回数 | ||
|---|---|---|---|---|---|---|---|
| failure | 236 | clinician | 16 | obesity | 9 | ||
| heart | 217 | function | 16 | activity | 8 | ||
| patient | 145 | infarction | 16 | advanced | 8 | ||
| risk | 53 | american | 15 | adverse | 8 | ||
| disease | 49 | arb | 15 | atrial | 8 | ||
| ventricular | 42 | blood | 15 | current | 8 | ||
| mortality | 41 | cardiovascular | 15 | drug | 8 | ||
| -rsb-_NN | 39 | hypertension | 15 | evaluation | 8 | ||
| therapy | 39 | severe | 15 | higher | 8 | ||
| inhibitor | 35 | they | 15 | hydralazine | 8 | ||
| not | 35 | à-blocker | 14 | important | 8 | ||
| you | 34 | weight | 14 | mild | 8 | ||
| symptom | 33 | chronic | 13 | morbidity | 8 | ||
| trial | 33 | circulation | 13 | more | 8 | ||
| ejection | 30 | diabetes | 13 | placebo | 8 | ||
| fraction | 30 | digoxin | 13 | primary | 8 | ||
| myocardial | 28 | management | 13 | pulmonary | 8 | ||
| investigator | 27 | significant | 13 | addition | 7 | ||
| it | 27 | survival | 13 | all-cause | 7 | ||
| other | 27 | diuretic | 12 | asymptomatic | 7 | ||
| who | 27 | dose | 12 | benefit | 7 | ||
| clinical | 26 | exercise | 12 | change | 7 | ||
| coronary | 26 | more | 12 | congestive | 7 | ||
| dysfunction | 26 | physical | 12 | controlled | 7 | ||
| cardiac | 25 | which | 12 | day | 7 | ||
| factor | 25 | diastolic | 11 | disorder | 7 | ||
| hospitalization | 25 | functional | 11 | enalapril | 7 | ||
| artery | 24 | history | 11 | even | 7 | ||
| effect | 23 | natriuretic | 11 | f | 7 | ||
| that | 23 | test | 11 | greater | 7 | ||
| also | 22 | condition | 10 | however | 7 | ||
| systolic | 22 | control | 10 | hypertrophy | 7 | ||
| guideline | 21 | diagnosis | 10 | information | 7 | ||
| less | 21 | implantation | 10 | j.jacc | 7 | ||
| level | 21 | large | 10 | many | 7 | ||
| pressure | 21 | peptide | 10 | population | 7 | ||
| class | 20 | renal | 10 | prevention | 7 | ||
| such | 20 | significantly | 10 | quality | 7 | ||
| what | 20 | specific | 10 | reduction | 7 | ||
| cardiomyopathy | 19 | standard | 10 | result | 7 | ||
| study | 19 | symptomatic | 10 | sign | 7 | ||
| treatment | 19 | abnormality | 9 | sinus | 7 | ||
| I | 18 | agent | 9 | smoking | 7 | ||
| rate | 18 | decompensated | 9 | status | 7 | ||
| death | 17 | evidence | 9 | support | 7 | ||
| outcome | 17 | group | 9 | systemic | 7 | ||
| when | 17 | high | 9 | volume | 7 | ||
| acute | 16 | left | 9 | ace | 6 | ||
| care | 16 | lower | 9 | blocker | 6 | ||
| cause | 16 | medical | 9 | combination | 6 |